-The Business Standard Still waiting for a crackdown on antibiotic over-prescription According to a recent study in the Lancet Infectious Diseases journal, the drug-resistant bacterial strain known as New Delhi metallo-beta-lactamase 1, or NDM-1, has spread to 40 countries. This is quite remarkable, given that it was only discovered in 2008 in the UK, among patients who had recently been hospitalised in India. The “superbug”, as it is commonly known, is...

-The United Nations The number of people with high blood pressure and diabetes is drastically increasing in both developed and developing countries, according to a United Nations report released today. “This report is further evidence of the dramatic increase in the conditions that trigger heart disease and other chronic illnesses, particularly in low- and middle-income countries,” said the Director-General of the World Health Organization (WHO), Margaret Chan. “In some African countries, as...

-The Times of India India's space agency Isro bent rules for private firm Devas to sign a deal for multimedia services, projecting a paltry Rs 1,120 crore revenue over a 12-year period that would not even have covered the cost of launching two satellites for the promised service, the Comptroller and Auditor General (CAG) has said.  In a report submitted to Parliament on Tuesday, the official auditor gave the Prime Minister's Office...

The Government of India has formally launched the news Guidelines of the MGNAREGA based on the Mihir Shah Committee report. The news guidelines include many new works under conservation activities and it strengthens the hands of the village panchayats and gram sabhas. However, the list of works does not include the activities under the system of rice intensification (SRI) which encourages scientific method of paddy cultivation with better yield in...

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...